TRANSKRIP 🔗
WEBVTT
00:00:07.200 --> 00:00:09.039
Welcome back to the accelerators podcast.
00:00:09.599 --> 00:00:12.240
What are we doing on how to do that?
00:00:14.880 --> 00:00:19.760
So are not and they represent our own opinions and not those of our employers.
00:00:20.239 --> 00:00:21.359
Thanks for being here.
00:00:21.519 --> 00:00:23.120
Let's get on with the show.
00:00:25.120 --> 00:00:27.760
So so welcome back to the Accelerators Podcast.
00:00:27.839 --> 00:00:29.359
Uh this is Matt Breaker.
00:00:29.440 --> 00:00:36.640
It's been a while, but I have a really, really exciting guest today for uh discussion we're gonna have um uh for our new episode.
00:00:36.799 --> 00:00:41.600
Uh and uh why don't you go ahead and just introduce yourself and kind of let us know where you're coming from and we'll we'll go from there.
00:00:41.920 --> 00:00:43.119
Yeah, well thanks, Matt.
00:00:43.280 --> 00:00:46.399
Um really appreciate the opportunity to join you for your podcast today.
00:00:46.560 --> 00:01:00.159
I uh greatly enjoyed being able to um join you last September in 2025 uh to give uh uh overview of what Ganotile was, and really grateful to join you again today, especially after all the great progress over the past year.
00:01:00.320 --> 00:01:10.560
Um, so I'm Mike Garcia, I'm a CNS radiational oncologist, and I'm also chief medical officer and head of clinical development at GT Medical Technologies, which is the maker of Ganotile.
00:01:11.359 --> 00:01:11.760
Awesome.
00:01:11.840 --> 00:01:12.879
Yeah, thanks for coming back.
00:01:12.959 --> 00:01:13.920
I'm I'm excited about this.
00:01:14.000 --> 00:01:30.959
And what's changed actually, we'll talk about this more, but what's changed since the last episode is I now have a program in real life and and we're doing this, and and I'm actually very thankful for the like the the company and like the things that have been offered because it's really infused some excitement for me into our CNS program.
00:01:31.040 --> 00:01:34.319
And neurosurgeons are excited and we're thinking we're doing great medicine for our patients.
00:01:34.400 --> 00:01:39.120
And so I think it's it's a nice thing, it's been uh a nice evolution over the since we last talked.
00:01:39.439 --> 00:01:40.159
That's great, Matt.
00:01:40.319 --> 00:01:49.840
Yeah, we've been thrilled to partner with you and your center um in helping patients have access to this modality and provide you with another option as you take uh great care of your patients.
00:01:50.159 --> 00:01:51.280
Yeah, yeah, thanks.
00:01:51.439 --> 00:01:52.799
So let's just dive right in.
00:01:52.879 --> 00:01:54.719
So today we're gonna talk about the road study.
00:01:54.799 --> 00:01:56.239
I think that'll be the bulk of our discussion.
00:01:56.400 --> 00:02:00.959
We'll talk about a few other things, but the goal of this podcast is to kind of discuss this recent study.
00:02:01.120 --> 00:02:18.240
Um, I actually uh had heard about this uh, you know, like we saw the conference presentation, I heard about it coming, and then and then what was funny to me is I saw the I was at Astro, I was in a cab, like riding to go meet some friends for dinner, and I saw the the trucks driving around with the exciting publication.
00:02:18.400 --> 00:02:20.080
And so I think this has been really cool.
00:02:20.240 --> 00:02:30.080
And and as I mentioned before, it's like it's been it's generated so much fascinating discussion between me and one of our neurosurgeons, just like truly nerding out about the science of of brain mats and kind of how we treat them.
00:02:30.159 --> 00:02:32.560
And I think it's been been really fun for me.
00:02:32.719 --> 00:02:34.400
Um, so maybe we can just start.
00:02:34.479 --> 00:02:36.240
I think people are familiar with the study.
00:02:36.319 --> 00:02:39.280
It's been talked about quite a bit online and in clinics, I'm sure.
00:02:39.439 --> 00:02:46.000
But maybe we can start just by you giving a summary of the study and the top line results, and then we'll kind of dive into some of the details.
00:02:46.400 --> 00:02:46.960
Absolutely.
00:02:47.199 --> 00:02:56.159
So Rhodes is a phase three multi-institutional uh randomized trial uh for patients with surgical brain metastases.
00:02:56.639 --> 00:03:02.319
Um, as you know, brain metastases are really common for patients with metastatic cancer.
00:03:02.400 --> 00:03:09.039
Um, and many patients with brain metastases need to have resection for symptomatic meds, large meds causing edema.
00:03:09.599 --> 00:03:26.159
And so um, what Rhodes did was to look at the current standard of care, which is surgery plus post-operative stereotactic radiation, and compare it to another methodology, surgery with uh implantation of gametile, also called tile-based radiation therapy.
00:03:26.319 --> 00:03:35.919
So, this is a randomized trial, really, between surgery plus postoperative SRT versus surgery plus immediate initiation of radiation with gametile.
00:03:36.319 --> 00:03:37.919
It was a one-to-one randomization.
00:03:39.039 --> 00:03:43.919
High-level inclusion criteria for patients with surgical brain metastases.
00:03:44.080 --> 00:03:51.680
They could have up to five additional non-surgical brain metastases that needed um treatment.
00:03:52.000 --> 00:03:56.400
And they could have tumors from two to seven centimeters in size.
00:03:57.120 --> 00:04:06.400
Um, for patients who received uh post-optive stereotactic radiation, they all received radiosurgery to any non-index lesion, non-surgical brain tumor.
00:04:06.639 --> 00:04:15.360
Um, and for patients randomized to be gametile arm, they had gametile for the reception cavity and radiosurgery for non any non-receptive tumors.
00:04:15.759 --> 00:04:18.240
That's the sort of high-level design of the study.
00:04:18.879 --> 00:04:30.480
This study um read out at ASCIIO 2026 and was uh accepted for publication as a rapid communication in JCO, which came out on September
Load full transcript
28th.
00:04:30.720 --> 00:04:36.399
And happy to say that just a couple of days ago it was published in its final form in JCO.
00:04:36.480 --> 00:04:40.639
So the PDF is available online and in the in the in the final version of the publication.
00:04:40.720 --> 00:04:42.560
So I encourage the reader to check it out.
00:04:42.639 --> 00:04:46.240
But now I will go through some of the high-level findings.
00:04:46.800 --> 00:04:51.439
So the two co-primary endpoints, the study of two co-primary endpoints.
00:04:52.000 --> 00:04:57.199
One was time to surgical bed recurrence, which is uh purely a local control endpoint.
00:04:57.600 --> 00:04:59.759
Time from surgery to recurrence.
00:05:00.000 --> 00:05:06.800
The other co-primary endpoint was surgical bad recurrence for your survival, meaning time to recurrence or death, whichever came first.
00:05:06.879 --> 00:05:09.920
In other words, how long are patients living without a recurrence?
00:05:10.639 --> 00:05:30.399
Um, so for the primary endpoint of time to surgical bed recurrence, the median time to recurrence was not yet reached on the gamma tile arm and was 17.4 months on the SRT arm with a hazard ratio of 0.06 and a p-value of 0.007.
00:05:31.439 --> 00:05:35.839
Um, that was at a median follow-up of 12.9 months.
00:05:35.920 --> 00:05:36.079
Okay.
00:05:36.319 --> 00:05:38.319
So that was the median follow-up of the study.
00:05:38.720 --> 00:05:49.839
The accumulative incidence, which is um another way of looking at recurrence, was 1.3% in the gametile arm versus 15.4% in the SRT arm.
00:05:50.319 --> 00:06:05.360
For the other co-primary endpoint, surgical bed recurrence-free survival, the median was not yet reached on the gametile arm and was 10.91 in the SRT arm with a hazard ratio of 0.48, p-value 0.0021.
00:06:05.759 --> 00:06:07.680
Those are the two co-primary endpoints.
00:06:08.000 --> 00:06:11.680
A secondary endpoint, the key secondary endpoint was overall survival.
00:06:11.839 --> 00:06:16.720
And that I know this is generating some of the buzz, so I would love to kind of nerd out on this finding with you later.
00:06:17.360 --> 00:06:29.279
Um, but the median overall survival on the Gallantile arm was 42.5 months versus 17.6 months on the SRT arm with a hazard ratio of 0.59 and a p-value of 0.032.
00:06:29.439 --> 00:06:32.560
So those are the key efficacy findings of the road study.
00:06:32.959 --> 00:06:43.199
First of all, I just want to sort of congratulate you guys because like I've done trials, you know, especially of like kind of I know we talked actually, I'd encourage people to listen to the prior podcast because we talked about a lot of history there.
00:06:43.279 --> 00:06:58.879
So it's not like a new technique, but one of the things that my neurosurgeon and I have sort of talked about is like just how crazy if you look back at the way they kind of used to do brachytherapy per brain and like how elegant this seems and how easy it seems just in you know, operatively is just pretty funny.
00:06:58.959 --> 00:07:08.079
But but I think um, you know, it must be, I think just in general for anyone that's like doing studies or trying to kind of do the science, as people say, it this is just really exciting.
00:07:08.160 --> 00:07:09.199
So congratulations on that.
00:07:09.279 --> 00:07:15.040
And I think you must, it must feel pretty good to see such great efficacy from kind of a new approach for something that's been a struggle for our field.
00:07:15.360 --> 00:07:16.560
I appreciate that, Matt.
00:07:16.720 --> 00:07:21.519
Um that means a lot, and and really, really happy now that patients could have a better option.
00:07:21.680 --> 00:07:40.000
Um, and and as you mentioned too, brain breaking therapy has come a long ways and has evolved uh technologically um and and grateful that it is now uh a type of modality that is easy to apply um and and patients have can have easier and widespread access to it, especially given these results.
00:07:40.800 --> 00:07:42.319
Yeah, so I think so that's really cool.
00:07:42.399 --> 00:07:47.040
And I and I don't want to um, again, like I this is not um this this is not like sponsored or anything.
00:07:47.120 --> 00:07:50.399
I'm not trying to overhype things, but I just think it's a general statement.
00:07:50.480 --> 00:07:55.839
It's like when you work on something new and you're not sure that it's gonna make a difference for people, and then you get this kind of a result, it's pretty exciting.
00:07:56.079 --> 00:08:00.480
We've had a couple of other things like that in radiation recently, which has been great.
00:08:00.720 --> 00:08:08.399
So, so what I did, what I thought was interesting, we talked about this kind of leading into this, is that there's been, I thought the discussion about this online was really good.
00:08:08.480 --> 00:08:15.920
Um, it was it was very uh like there was no fighting, which I like to see because there's been a lot of arguing with Rhinox online right lately.
00:08:16.079 --> 00:08:22.480
But and I thought there was some really clever um kind of uh kind of insight into the study, and and you could call them critiques.
00:08:22.800 --> 00:08:26.319
What I actually did to frame this, it's the modern era now when we do podcasts.
00:08:26.399 --> 00:08:35.519
So I so I actually went to open evidence to ask about some controversies that it thought about the study, um, or just discussion points to kind of see what it what it thought.
00:08:35.679 --> 00:08:43.039
And it came up with some, and I thought they were pretty interesting, and then these do align kind of with what you all have been hearing from people, the discussion online.
00:08:43.200 --> 00:08:52.480
And so I think one of the nice things about this study is it's pretty clean, so to speak, and the discussion points are very educational for people that are kind of learning about how to interpret trials.
00:08:52.799 --> 00:08:58.320
So the first one, um, this was
actually labeled by open evidence as controversy number three.
00:08:58.399 --> 00:09:00.240
I'm gonna save some of the other ones for later.
00:09:00.399 --> 00:09:02.879
But the I thought this was funny, I laughed out loud when I read it.
00:09:02.960 --> 00:09:06.159
They said, is the hazard ratio of 0.06 too good?
00:09:07.279 --> 00:09:12.080
And I'm like, well, that's a weird way to frame it for patients who I'm sure would want to see as best as they can get.
00:09:12.159 --> 00:09:23.440
But I think that's a question, is like, you know, and and I think the overall survival finding was like kind of the one that people are talking about as is, you know, there needs to be maybe longer follow-up or more to calm to get clarity on it.
00:09:23.519 --> 00:09:26.159
But I wanted to get your thoughts on that discussion point.
00:09:26.639 --> 00:09:26.960
Sure.
00:09:27.120 --> 00:09:30.559
Yeah, so let's talk first about the hazard ratio of 0.06.
00:09:31.200 --> 00:09:38.240
There were there was one, there were there were 12 recurrences in the SRT arm total.
00:09:38.480 --> 00:09:38.639
Yeah.
00:09:38.879 --> 00:09:41.519
There was one, there was only one recurrence in the gamutel arm.
00:09:42.159 --> 00:09:44.639
And so the stats take that into account.
00:09:44.960 --> 00:09:53.600
So the hazard ratio was 0.06, but if we look at a 95% confidence interval, it was 0.01 to 0.46.
00:09:54.240 --> 00:10:03.039
So that that may be a somewhat relatively wide confidence interval, but it takes into account the relatively low number of vets.
00:10:04.080 --> 00:10:19.440
Um, but even if we look at that the upper bound, um 0.46, so kind of on the extreme of like the worst case scenario, if you will, 0.46, that's still over a 50% reduction in risk and is still very clinically meaningful.
00:10:19.600 --> 00:10:33.840
Um it's really that one single event, such a low number of events on the gamutel arm that makes the hazard ratio so extreme, with the other end of the confidence interval being 0.01, meaning a 99% reduction in the hazard.
00:10:34.240 --> 00:10:45.120
So although the point, although the 0.06 is quite extreme, I think it reflects um the really good outcome on the gamma tile arm.
00:10:45.519 --> 00:11:02.080
And then the somewhat wide, although I would still say relatively tight hazard ratio, and that is clearly less than one, um, reflects the relatively low number of events across the triad, which actually I think is also encouraging that these patients overall did quite well on both arms.
00:11:02.399 --> 00:11:02.639
Yeah.
00:11:02.799 --> 00:11:03.759
It's funny you said it.
00:11:03.840 --> 00:11:08.159
So I actually pulled a tweet about this because there was a really fascinating discussion.
00:11:08.320 --> 00:11:23.360
I've sent this out a couple of times, but this uh doctor, radiation oncologist Stas Lazarev was having a discussion with, I think, I think she's a biostatistician, but Aditya Patel, and and this is like at uh A D I T Y
A P Circo 77.
00:11:23.519 --> 00:11:26.080
I'll post this in the show notes so people can go look at these.
00:11:26.320 --> 00:11:29.279
But um this was this was exactly what was said.
00:11:29.519 --> 00:11:45.039
And this is actually the discussion I had with my with with the neurosurgery team that we work with, is like, is that, you know, there's always, I think one of the most interesting things about being a physician in clinic, and then you know, one of the most challenging things is that you have to interpret studies that have inherent uncertainty in them.
00:11:45.279 --> 00:11:50.480
But even the upper bound of that confidence interval represents an over 50% reduction of recurrence.
00:11:50.559 --> 00:11:53.600
And frankly, for me, it's hard not to get excited about that.
00:11:53.759 --> 00:12:01.120
And I do think some of the discussion online, so like this person said, calling it merely a signal dramatically understates the result.
00:12:01.360 --> 00:12:03.200
I do think that that's a fair comment.
00:12:03.279 --> 00:12:13.600
I do feel like the uh in other settings, like if this was a drug, for example, these findings would be, you know, standing applause talked about by every news outlet.
00:12:13.759 --> 00:12:21.519
So I do think that there was a little bit of underplaying of the efficacy findings here, and and it's probably worth just considering that, I think, for radiation oncologists.
00:12:21.759 --> 00:12:21.919
Yeah.
00:12:22.159 --> 00:12:23.519
I couldn't agree anymore.
00:12:24.000 --> 00:12:24.320
Yeah.
00:12:24.399 --> 00:12:25.759
So so that's so that was one.
00:12:25.919 --> 00:12:27.360
I think let's move on to the next one.
00:12:27.440 --> 00:12:28.480
This I think is a really good one.
00:12:28.559 --> 00:12:29.360
I like this one a lot.
00:12:29.519 --> 00:12:32.960
So, so this was um this was our our second discussion point.
00:12:33.039 --> 00:12:35.919
This was open evidence's controversy, too.
00:12:36.159 --> 00:12:44.720
But basically pointing out to the open label design, the MIIT population, the unblinded imaging uh issue.
00:12:44.879 --> 00:12:49.519
Um, and so so that um is something uh that I kind of wanted to ask you about.
00:12:49.600 --> 00:12:52.240
So, so why was this MIIT chosen?
00:12:52.399 --> 00:12:53.679
How did it compare to the IIT?
00:12:53.919 --> 00:13:01.120
Can we talk a little bit about this like enhancement versus true recurrence being a hard call on MRIs after cavity resections and things like that?
00:13:01.519 --> 00:13:01.919
Absolutely.
00:13:02.080 --> 00:13:07.200
Thanks for asking this question, and then we get to kind of go into more detail on the um population analyses.
00:13:07.679 --> 00:13:16.720
So the protocol, when it was designed, specified that the analyses would be performed on what was called the modified intent to treat.
00:13:16.960 --> 00:13:25.679
The modified intent to treat was defined as patients who had surgery and histologic confirmation of brain metastasis.
00:13:26.320 --> 00:13:39.679
A major reason that it was chosen to do the analysis on that population is that there is the possibility when a patient has an enhancing tumor that needs resection that there's going to be a surprise histology, such as glioblastoma, for instance.
00:13:40.240 --> 00:13:48.240
And you wouldn't really want those patients in the main analysis because they're obviously could confound the uh the outcomes.
00:13:48.559 --> 00:13:55.120
So the modified attempt of treat was chosen to exclude patients who had surprised histologies.
00:13:55.440 --> 00:13:57.039
And that's why it was chosen.
00:13:57.200 --> 00:14:04.720
Um, and so the the primary analyses in the paper and all the endpoints that I cited um were on the modified intent of treat analysis.
00:14:05.039 --> 00:14:17.279
Importantly, though, um, because of this, you know, certainly certain val certainly a valid um critique, as anytime you exclude patients from the original randomization, you can introduce bias.
00:14:17.600 --> 00:14:30.960
And so the intent to treat is the golden standard for analysis on a randomized trial, and the authors present all of the outcomes also on the pure intent to treat all 230 randomized patients.
00:14:31.279 --> 00:14:47.360
And in fact, the um the two primary endpoints as well as the overall survival survival finding were were all positive, but um superior for gametile in the intent to treat the population.
00:14:47.519 --> 00:14:52.480
And so I I encourage the readers to check out those um those findings in the paper.
00:14:52.639 --> 00:14:56.399
The hazard ratios were very similar, the p-values were very similar.
00:14:56.879 --> 00:15:01.600
Yeah, and I think I think what's and again, I'm gonna like kind of point people to this online discussion.
00:15:01.759 --> 00:15:07.840
It's really fascinating because I think what they're touching on is you're sort of between a rock and a hard place here, right?
00:15:07.919 --> 00:15:23.519
Like I think that the critiques of this endpoint and the way that it was that it was like kind of uh resulted, or the way that it was analyzed in the study, there's not I can't, I personally could not think of a better or different way to do it that would make the findings more certain, if that makes sense.
00:15:23.679 --> 00:15:25.840
And and so I actually wanted to point one more quote.
00:15:25.919 --> 00:15:38.159
I'm not gonna just keep pulling quotes from online, but one thing that that I thought Seth said that I thought was really interesting is is it's clear that in all of this critique, there's no question that that people believe the local control signal is real.
00:15:38.320 --> 00:15:45.120
Uh the quote is specifically local control signal is real, but the magnitude may be much may be much less dramatic than the headline suggests.
00:15:45.279 --> 00:15:49.039
Gamma tile may absolutely be a reasonable option for select patients.
00:15:49.120 --> 00:15:50.879
And I'm
gonna editorialize this a little.
00:15:51.279 --> 00:15:58.240
That is the same thing that people at radiation colleges said about the particle study with prostate, which had not even a hint of benefit.
00:15:58.399 --> 00:16:07.759
So I do think there's I think it's possible to be biased about things that are new that you may or may not have in your repertoire as a practicing physician.
00:16:07.840 --> 00:16:16.960
And I'm getting the sense that, and we're gonna talk about this later, but I'm getting the sense that like one of the things here is that you can't just go do this like tomorrow if you want to, if you don't have a program yet.
00:16:17.120 --> 00:16:21.360
But I I'll tease a little bit that I personally feel like setting up a program is pretty straightforward.
00:16:21.440 --> 00:16:23.679
And so I think it's something that should be considered.
00:16:23.840 --> 00:16:33.759
And one thing that's really interesting too is I'll remind people that like you have this push and pull here where the effectiveness of the treatment is going to harm your certainty of that HR, right?
00:16:33.919 --> 00:16:36.720
So, so like if you don't have recurrences, that's what we all want.
00:16:36.799 --> 00:16:42.879
That's why we're doing this, but it limits your statistical ability to give kind of strong numbers to to patients in counseling.
00:16:42.960 --> 00:16:50.720
But but I think I don't know, I haven't I've never seen any critique that anyone has said that they don't believe that this is a very effective treatment.
00:16:50.879 --> 00:16:59.440
And in my opinion, it is likely to be more effective than post-op SRS, especially with larger lesions or other factors that could cause worsening local control.
00:16:59.519 --> 00:17:00.720
We'll talk about that in a little bit.
00:17:01.039 --> 00:17:01.440
Absolutely.
00:17:01.519 --> 00:17:09.440
And I mean, I would and I would go, I would I would respectfully say that this finding is much more than a signal.
00:17:09.519 --> 00:17:15.359
It's it's a finding on a pre-specified primary endpoint on a randomized multi-institutional trial.
00:17:15.519 --> 00:17:17.759
It's it's much more than a signal.
00:17:17.839 --> 00:17:20.400
It is a it is a definitive finding.
00:17:20.640 --> 00:17:28.559
And and for all those reasons, I do think that this establishes that um that tile-based radiation therapy is is superior.
00:17:28.720 --> 00:17:37.599
Um, and I think should motivate centers to um move towards adopting a program if they don't, so they can offer this option to patients.
00:17:37.920 --> 00:17:38.720
Yeah, I do agree.
00:17:38.799 --> 00:17:42.240
And I think, I mean, obviously, you know, I'm excited about the technology myself.
00:17:42.400 --> 00:17:55.920
There's like, you know, like clearly we we don't have like a naysayer to kind of balance this discussion, but frankly, I would just encourage people to think about globally how they interpret studies in oncology and what we do in other aspects of care, right?
00:17:56.079 --> 00:18:03.279
And so if you kind of set this uh objectively against those kinds of findings, I think your statement is is pretty objectively true.
00:18:03.440 --> 00:18:03.599
Yeah.
00:18:03.920 --> 00:18:04.720
Yeah, totally.
00:18:04.960 --> 00:18:14.720
I think I think what you're saying is, and I completely agree with is it's it's it's fair to have a common standard across trials and not have one standard for one trial and a different standard for another trial.
00:18:14.960 --> 00:18:15.200
Right.
00:18:15.359 --> 00:18:25.039
Can I ask also, so did you guys did we so did you all discuss kind of like non-inferiority trial design, or can you share a little bit about how that was picked as the overall design of the study?
00:18:25.279 --> 00:18:25.680
For sure.
00:18:25.759 --> 00:18:33.519
Yeah, I wasn't part of the original design of the study, um, but I can speak to the non-inferiority design and some of the rationale.
00:18:33.599 --> 00:18:42.160
And then I would love to also geek out a little bit on stats and how superiority could be shown on a non-in-inferiority trial design study because this question comes up a lot and is of great interest.
00:18:42.559 --> 00:18:46.880
I did not know that until like a year or so ago, and I learned that on Twitter basically.
00:18:46.960 --> 00:18:48.160
But yeah, it's an important point to teach.
00:18:48.240 --> 00:18:48.319
Yeah.
00:18:48.799 --> 00:18:49.519
Yeah, let's talk about it.
00:18:49.680 --> 00:18:49.839
Yeah.
00:18:50.079 --> 00:18:53.279
So this study was designed initially as a non-inferiority design study.
00:18:53.440 --> 00:18:58.079
So um when is it appropriate to do a non-inferiority design study?
00:18:58.240 --> 00:19:17.759
Well, it's appropriate when you expect that um uh experimental treatment is not going to be worse in efficacy, but could add some advantages to the patients, such as um more convenience, uh less toxicity, um, more accessibility.
00:19:18.160 --> 00:19:27.200
Uh so it ways to improve things for patients without necessarily uh uh improving efficacy.
00:19:27.680 --> 00:19:29.680
And that was the thought with Gamatile.
00:19:30.000 --> 00:19:43.359
Um because post-operative SRT can be sometimes logistically challenging, um sometimes you know, or we know associated with you know radiation necrosis, some patients never make it to post-operative SRT.
00:19:43.440 --> 00:19:50.799
They may live in uh towns that don't have um uh access to radiation oncology, they may not have transportation, etc.
00:19:51.200 --> 00:19:57.599
Um, it's the thought was that gametile solved some of these solutions by being implanted at time of surgery.
00:19:57.839 --> 00:20:10.880
So that was the sort of philosophy of why gametile um could improve things for patients without hurting efficacy, and just and that was a justification for a non-inferiority design trial.
00:20:11.200 --> 00:20:12.960
And so that's why that was done.
00:20:13.519 -->
00:20:20.240
But for a non-inferiority design study, superiority can absolutely be shown.
00:20:20.400 --> 00:20:22.400
And it all has to do with the hazard ratio.
00:20:22.559 --> 00:20:37.279
So for a non-inferiority design study, there's a null hazard ratio that is greater than one, but close enough to one that one could say um is acceptable and and it is not detrimental to efficacy.
00:20:37.599 --> 00:20:50.720
As long as the 95% confidence interval does not overlap with that null hazard ratio, such as 1.2, and is less than that, but overlaps with one, you can conclude non-inferiority.
00:20:51.200 --> 00:21:01.039
However, if the confidence interval at the end of the study is less than one and does not overlap with one, you can conclude superiority and non-inferiority.
00:21:01.279 --> 00:21:08.240
And in the discussion of the JCO paper, um, there's a paragraph um on this very concept.
00:21:08.400 --> 00:21:17.519
And it's and the author cites a really helpful New England Journal of Medicine article that really goes into depth on non-inferiority design studies.
00:21:17.599 --> 00:21:29.599
And there's a there's a really, really nice figure that shows all the different hazard ratio scenarios and then what you can conclude, such as non-inferiority and superiority, for instance, or just non-inferiority.
00:21:29.759 --> 00:21:36.559
Uh so this is definitely a method methodologically valid statistical um um concept.
00:21:36.720 --> 00:21:41.039
And I would encourage the readers to check out that uh that resource that cited in the discussion.
00:21:41.599 --> 00:21:43.759
Hey, I've so is there gonna be plans?
00:21:43.839 --> 00:21:45.920
I don't know if you can share this or not, but there are plans.
00:21:46.160 --> 00:21:47.759
Are there plans for long term follow up?
00:21:47.839 --> 00:21:55.119
Because I do know that like some of the main critiques that uh I was reading online are sort of unanswerable at this point in follow up, right?
00:21:55.279 --> 00:21:57.279
And so I think for me, I'd love to see it.
00:21:57.440 --> 00:22:02.319
Just again, kind of nerd interest, but but But I think uh uh do you guys have plans for that?
00:22:02.640 --> 00:22:21.119
Yeah, I I I know that the that the authors um and the PIs do have plans for a long-term follow-up and to include additional uh data that so I this I would love to talk a little bit more about overall survival because I do think that longer follow-up could hopefully shed more light on this overall survival finding.
00:22:21.279 --> 00:22:21.599
Yes.
00:22:22.160 --> 00:22:25.920
Um and so I do know that there is interest in collecting additional data.
00:22:26.079 --> 00:22:48.720
Because the trial was not initially designed to look at overall survival, the the trial did not collect granular data on things that can better assess a mechanism for overall survival, such as um timing of resuming systemic therapy after surgery, types of systemic therapy, and other other important things for prognosis.
00:22:48.880 --> 00:23:04.079
Um and so doing a long-term follow-up could further you know evaluate overall survival with longer median follow-up, but then also you could include additional data that that looks at the mechanism for uh overall survival benefit.
00:23:04.400 --> 00:23:09.680
Yeah, and I would love to kind of just go into a little bit more about the overall survival finding, if that's okay.
00:23:10.000 --> 00:23:10.559
Yeah, let's do it.
00:23:10.640 --> 00:23:11.359
Yeah, yeah, definitely.
00:23:11.599 --> 00:23:15.119
So definitely like it was a this is a surprising finding, right?
00:23:15.200 --> 00:23:27.759
Like we're we're taught, and you know, over the past decades, we have not really seen overall survival benefit from brain radiation, with a couple caveats that I've talked about.
00:23:27.920 --> 00:23:35.759
But in general, um, focal brain radiation for brain metastases has not been shown to lead to overall survival.
00:23:35.920 --> 00:23:41.200
And so this is understandably uh uh somewhat of a surprising finding in 2026.
00:23:41.519 --> 00:23:43.599
There's a couple of things to consider though.
00:23:43.839 --> 00:23:49.839
Um, at the plenary session, there were two uh studies that were presented.
00:23:50.079 --> 00:23:56.480
One was the Alliance study, which was also a uh uh a trial for resected brain meds.
00:23:56.559 --> 00:24:02.640
Patients were randomized to post-operative single fraction radiosurgery or fractionated SRT.
00:24:03.039 --> 00:24:10.799
Patients with fractionated SRT had superior local control compared to single fraction radio surgery, and they also had an overall survival benefit.
00:24:11.039 --> 00:24:21.839
There was another study, um, NRGCC009, which it was it was a different clinical context, and these are patients with intact brain metastases from small cell lung cancer.
00:24:21.920 --> 00:24:24.720
So a different clinical scenario.
00:24:25.039 --> 00:24:28.079
Patients randomized a whole brain versus radiosurgery.
00:24:28.319 --> 00:24:32.880
The patients who were randomized to radiosurgery had a longer overall survival.
00:24:33.200 --> 00:24:46.400
So just taking a step back, in 2026, we now have three trials, ultra contemporary, which have shown an overall survival benefit for focal high-quality radiation in the brain.
00:24:46.720 --> 00:24:58.559
So I do think that although in the past few decades, overall survival has been elusive, the benefit uh on brain titles in 2026 we've now seen grief.
00:24:58.960 --> 00:25:06.319
So I think there is something to this, and I think that of course we should try to better understand why, but I think that we should take this finding seriously.
00:25:06.480 --> 00:25:06.640
Yeah.
00:25:06.799 --> 00:25:22.720
Um, it doesn't mean that we um shouldn't always you know be um uh skeptical initially scientifically and ask questions, but I do think that this merits a lot of attention and um and we need to take these overall survival
findings seriously.
00:25:23.039 --> 00:25:27.039
So, why could there be an overall survival finding on Rhodes?
00:25:27.359 --> 00:25:36.000
I think that there are a few plausible mechanisms, and these are speculative given the limitations of the study that I mentioned before, but I think they're worth talking about.
00:25:36.880 --> 00:25:54.480
One is if patients are able to resume systemic therapy quicker than they would be with postoperative SRT, then it would make sense that getting back on cancer-directed therapy systemically quicker could lead to an overall survival advantage.
00:25:55.119 --> 00:26:18.079
One criticism of the trial has been that there were not um more neurological deaths on the SRT arm, meaning you would expect the local control benefit to directly affect survival if the um if the local control benefit led to improvement in neurocognitive uh survival.
00:26:18.880 --> 00:26:30.160
But if patients are able to resume systemic therapy quicker, then you could potentially prevent deaths from extracranial um extracranial disease.
00:26:30.400 --> 00:26:32.720
So I think that's one plausible mechanism.
00:26:33.119 --> 00:26:40.400
Um that is supported by a uh unplanned subset analysis of patients with single brain maths versus multiple brain mats on the study.
00:26:40.559 --> 00:26:43.759
The overall survival benefit held for patients with single brain mets.
00:26:43.920 --> 00:26:55.119
Um, and that again like supports the notion that patients getting back on systemic therapy quicker because they didn't need any postoperative radiation to any non-index lesions, they were able to resume systemic therapy faster.
00:26:55.359 --> 00:27:01.359
I think another mechanism is when you have a recurrence that can be incredibly harmful for the patient for obvious reasons.
00:27:01.680 --> 00:27:10.240
A couple other reasons, other than um, you know, potentially causing a neurologic death, is that when a recurrence happens, these patients can need indexamathasone, right?
00:27:10.400 --> 00:27:15.680
And dexamathasone can somewhat be toxic, cause metabolic disturbances, they can affect the efficacy of immunotherapy.
00:27:15.839 --> 00:27:21.599
And so I think preventing a recurrence can be very meaningful systemically beyond the brain for those reasons.
00:27:21.680 --> 00:27:30.079
And sometimes those patients have to switch systemic therapies that were otherwise very, well, you know, very effective for extracranial disease.
00:27:30.480 --> 00:27:32.720
Um, so I think these are some plausible mechanisms.
00:27:32.799 --> 00:27:41.599
And then I forgot to mention too, when a patient has a recurrence, that can be psychologically devastating, cause a ton of you know anxiety, and and and can be demoralizing.
00:27:41.759 --> 00:27:47.359
So I think these are plausible mechanisms, but um, these are mechanisms that are being further investigated.
00:27:47.680 --> 00:27:55.119
I feel like there are also mechanisms that are going to be so hard to like definitively identify scientifically in studies, right?
00:27:55.279 --> 00:28:00.799
I mean, anyone that like works this space day to day, like there's just so much like chaos, right?
00:28:00.880 --> 00:28:02.079
There's just like things happen.
00:28:02.240 --> 00:28:03.759
People miss miss intervals.
00:28:03.839 --> 00:28:18.799
They, you know, and then one of the things I was talking about with my group is like, I know there's a lot of this teasing apart of uh, you know, we talked before about the IIT and the radiographic outcome and things like that, is this teasing apart of like necrosis versus you know recurrence.
00:28:19.039 --> 00:28:32.240
And it's like when you see that play out in real life, like I think that the the event of that coming up, whether it's is necrosis or necur recurrence, it like derails the cancer plans for the patients, like you just said, right?
00:28:32.319 --> 00:28:42.480
And and it's like the more I do this, the more I feel that there is something to the findings that you pointed out at the top of this part of the discussion that we're seeing across studies.
00:28:42.720 --> 00:28:46.079
Um, and it might be something that I'm I'm sure we will learn.
00:28:46.240 --> 00:29:02.240
Like the the CNS kind of investigators are doing such a great job lately of kind of teasing apart all this stuff, but but I I just I feel like in the literature there's this like sort of specter on of uncertainty around neurologic death and and what's happening with these patients where it's just really hard to capture statistically, so to speak.
00:29:02.400 --> 00:29:02.640
You know?
00:29:02.960 --> 00:29:04.240
100% agree.
00:29:04.559 --> 00:29:04.880
Okay.
00:29:05.200 --> 00:29:07.920
So so let's move on to another discussion point.
00:29:08.079 --> 00:29:11.680
Um, this one um actually was I thought this was a really fun one.
00:29:11.759 --> 00:29:23.279
Um, so there was some discussion, um, this surprised me a bit that there was like kind of uh um sort of critique of the SRT arm as a comparator on its in its own right.
00:29:23.519 --> 00:29:30.799
And so do you feel like the post op SRT was a weak comparator, or do you feel like it underperformed on the trial?
00:29:30.880 --> 00:29:32.000
Um, that kind of a thing.
00:29:32.160 --> 00:29:40.079
And then I do want to ask you about pre-op SRS because I saw that come up a little bit, but but I want to ask you first about your overall thoughts about the comparator arm and the control arm.
00:29:40.480 --> 00:29:49.119
The the control arm performed almost exactly as we would expect or SRT to perform.
00:29:49.279 --> 00:30:12.720
And the reason I can say that confidently is if we again look at the Alliance study that was presented at Astro, the the study that looked at fractionated SRT versus single fraction radiosurgery for for receptive brain mets, post post-operative cave radiation, the post-op the winning arm was the the fractionated SRT, the post-operative
fractionated SRT.
00:30:13.039 --> 00:30:15.759
The local control rate at one year was 87%.
00:30:17.440 --> 00:30:20.559
On the Rhodes trial, it was approximately 85%.
00:30:21.599 --> 00:30:25.440
So it performed consistently with the alliance study.
00:30:25.519 --> 00:30:25.920
And Dr.
00:30:26.079 --> 00:30:31.680
Prabhu, who was one of the discussants on the alliance study at the plenary at Astro, made that point.
00:30:32.000 --> 00:30:42.319
So we are seeing the SRT arm on roads perform consistent with the SRT arm fractionated on the uh alliance study.
00:30:42.559 --> 00:30:48.079
It's also not surprising given this was this was a study done at 32 uh sites across the country.
00:30:48.240 --> 00:30:49.920
So it's it's generalizable.
00:30:50.240 --> 00:30:59.759
And over 90% of the SRT on roads was fractionated, hence why it's consistent with the alliance study.
00:31:00.000 --> 00:31:08.559
So I would say that it performed consistent with what we are seeing in the ultra modern era for fractionated SRT, um, which is better than the historic.
00:31:08.799 --> 00:31:19.759
If you look at the practice changing study, single fraction radial surgery published in 2017 from the Hodge on Brown, the local control was much worse in the 70s.
00:31:20.000 --> 00:31:26.559
So we're seeing it um performed better than historic and consistent with other modern trials to date.
00:31:26.799 --> 00:31:36.160
But on the topic of post op SRT, one thing I want to talk about that I do think is underappreciated is how often patients don't make it to post-op SRT.
00:31:36.400 --> 00:31:36.799
Yes.
00:31:38.400 --> 00:31:39.039
Yeah, yeah.
00:31:39.200 --> 00:31:39.359
Yeah.
00:31:40.000 --> 00:32:08.079
I think we should talk about that because honestly, like this is the thing for me that was fascinating about the reaction to the study because ever since the beginning of when we've been talking, this is a significant uh, I believe, I mean, I again I don't work for GT Medical, but it seems to me that this is like a major reason to consider this treatment over post-op SRS is the time to treatment after resection and concerns about that.
00:32:08.160 --> 00:32:10.960
And before you give your thoughts, can I just share this for the for the audience?
00:32:11.440 --> 00:32:13.920
There's a study from 2021 by Roth O'Brien.
00:32:14.079 --> 00:32:20.160
It's it's a real-world time to cavity SRS study that looked at patients who had surgery and then post-op SRS.
00:32:20.400 --> 00:32:24.000
Overall local recurrence in this cohort was about 22%.
00:32:24.559 --> 00:32:27.920
And then they broke it out by time to SRS from surgery.
00:32:28.079 --> 00:32:29.599
I'm sure you're familiar with this study.
00:32:29.839 --> 00:32:34.240
Four weeks or less, the control, uh the local recurrence rate was only 2.3%.
00:32:34.960 --> 00:32:38.720
Four to eight weeks from surgery if you start radiation, 14.5%.
00:32:39.119 --> 00:32:41.200
And that was statistically significantly different.
00:32:41.519 --> 00:32:43.759
More than eight weeks, 48.5%.
00:32:44.559 --> 00:32:47.839
And then that's uh that's also significant from the baseline.
00:32:47.920 --> 00:32:54.079
And so this is something that once I started to look at this, uh, I turned around and looked at my own practice.
00:32:54.160 --> 00:32:56.000
Um, I think people know I'm in Denver.
00:32:56.079 --> 00:33:01.119
Uh Denver is like uh boss level challenging care coordination, in my opinion.
00:33:01.279 --> 00:33:05.839
There's just a lot of fragmentation of care, and people live all over and have all kinds of unique social challenges.
00:33:06.079 --> 00:33:10.079
And honestly, I haven't run the numbers in our practice, but this is a real concern of mine.
00:33:10.160 --> 00:33:18.480
And and so it's something that has uh, I would say, in our own practice, is probably the major point of discussion uh overall.
00:33:18.640 --> 00:33:32.640
Um, and and so it's something that uh I think was interesting to me how it's been talked about so much in the company materials, but it doesn't seem like it was really talked about in the discussion of the study by kind of a radiation oncologist at large.
00:33:32.880 --> 00:33:35.839
Yeah, I I so share your perspective.
00:33:36.000 --> 00:33:47.359
And I I practice in Arizona, I was brought up in New Mexico, so we kind of somewhat rural areas, and and I'm also sadly very familiar with this access to care issue.
00:33:47.599 --> 00:33:55.680
And oftentimes patients are coming into Phoenix to get their craniotomy, and then we're doing our very best to get them looped in with a local radiation oncologist.
00:33:56.160 --> 00:34:08.320
And it's so sad when we see them again, you know, weeks later with their tumor recurrence, or months later even, and and they hadn't had a they hadn't seen radiation oncology just despite everyone's efforts to try to get it, get them in.
00:34:08.400 --> 00:34:11.519
And there's complex social reasons for for that sometimes.
00:34:11.920 --> 00:34:31.599
And um, and on top of uh the the data that you cited for from the O'Brien paper, which which shows like the the importance of radiation delay, there's also some data um from uh prospective trials that show that actually a meaningful amount of patients never even make it to SRT.
00:34:31.760 --> 00:34:45.280
So there was a trial from a mortalist and kettering as well as um some preliminary data from a pre-op versus post-op SRT trial from MD Anderson that showed that that rate is 20 to 27% of patients never made it to SRT.
00:34:45.519 --> 00:34:47.199
On the run study, it was 18%.
00:34:47.599 --> 00:34:59.679
So it has been a criticism of Rhodes that patients on the SRT arm, some of them didn't make it to SRT, 18%, but that actually is less than what we see on other trials and probably less than what we see in the real world.
00:34:59.920 --> 00:35:11.840
So this is a really important, really important problem, and I think can be
underappreciated in our field, um, particularly because many, many of us are meeting these patients for the first time outpatient.
00:35:12.000 --> 00:35:14.719
We don't necessarily meet them at the time of craniotomy.
00:35:14.880 --> 00:35:24.000
So sometimes we don't have eyes on patients who have craniotomy, need post-op SRT, and never make it to a range oncologist for making it to SRT.
00:35:24.320 --> 00:35:27.840
Yeah, and I think it's worth pointing out, like it's not for lack of trying, right?
00:35:27.920 --> 00:35:37.920
I mean, one of the advantages of trials that probably everyone agrees is you even get extra kind of uh sort of administrative care coordination help out of a trials team, right?
00:35:38.000 --> 00:35:45.519
And even with that, I mean, you know, up almost 20% of patients like in trials is something that really is is is really shocking.
00:35:45.599 --> 00:35:47.360
And I think it rings true to me.
00:35:47.599 --> 00:36:00.079
And so we can, you know, I thought it was fun to talk about all the statistical uh, you know, discussion of the outcomes, but I feel like this is something that if people really reflect about their own practice, they're gonna see.
00:36:00.239 --> 00:36:07.920
And and like it's I mean, genuinely, if you go to the OR and watch this, it's like you you really get a feel for for how it's like immediate radiation.
00:36:08.000 --> 00:36:15.119
And I think I think it that's something that I would like to see people discuss more because I think it's a bigger deal than people have talked about overall.
00:36:15.440 --> 00:36:15.760
I agree.
00:36:15.840 --> 00:36:23.840
I mean, given that that peace of mind for the treatment team, the peace of mind for the patient, knowing that they're getting that immediate radiation, I think is really helpful.
00:36:24.079 --> 00:36:24.320
Yeah.
00:36:24.800 --> 00:36:36.559
Related to the topic, and not to bring it too much back to stats, but related to that topic, um, given given that you know that potential criticism for patients not making it to SRT, the authors did do a per-protocol analysis.
00:36:36.719 --> 00:36:41.039
So omitting those patients who didn't make it to SRT, which really is not a real, real thing.
00:36:41.199 --> 00:36:49.280
It's not a, you know, it's not a reality, but it just removing those patients as if as if 100% of patients make it to SRT.
00:36:49.519 --> 00:37:00.719
Um, comparing all the patients who only made it to SRT with the gamutale patients, the surgical bed recurrence and the surgical bedrocurrence free survival findings still help true.
00:37:00.960 --> 00:37:09.840
So even just purely looking at like the radiation modalities head-to-head, omitting patients who didn't make it to SRT, uh, gamutile still came out ahead.
00:37:10.079 --> 00:37:11.679
Yeah, I don't want to derail this too much.
00:37:11.760 --> 00:37:18.480
And this was uh, I'm gonna spring this question on you, but is there like, do you have a sense of the quality
of post op radiation given on the Rhodes trial?
00:37:18.559 --> 00:37:21.519
And like, were there um the when people did make it there?
00:37:21.599 --> 00:37:27.440
And they like if you're looking at just the uh the uh treated patients, was it high quality radiation?
00:37:27.519 --> 00:37:29.679
Were there any concerns about deviations and things like that?
00:37:30.079 --> 00:37:33.119
So I don't believe that there are concerns about deviations.
00:37:33.280 --> 00:37:46.000
The um the trial did provide guidance on dose of fractionation, specifically um 27 grain three fractions for a moderately sized cavity, 30 grain five, in keeping with you know, you know, modern clinical practice.
00:37:46.239 --> 00:37:52.400
Single fraction was allowed for small cavities, but as I mentioned, over 90% of patients have fractionated SRT.
00:37:52.559 --> 00:38:02.480
And I think that one thing that speaks to the overall quality on the SRT arm of the technical delivery is the overall outcome of uh 85% local control at one year.
00:38:02.559 --> 00:38:04.159
Again, that's that alliance study.
00:38:04.239 --> 00:38:08.159
So I think that we can feel confident that post-op SRT was given in a quality fashion.
00:38:08.480 --> 00:38:08.719
Good.
00:38:08.800 --> 00:38:09.679
Yeah, that's good to hear.
00:38:09.760 --> 00:38:21.440
And and actually, I was one thing I'll just share with our own experience as our program is growing is like there are there's some some data in the literature about quality in terms of post-placement dosemetry for brachytherapy with the device.
00:38:21.599 --> 00:38:27.199
And and I uh it's funny because like we, you know, we're a growing program, but our dosemetry has looked great.
00:38:27.280 --> 00:38:37.119
I mean, this is designed in a way where I feel like uh when I go and do this together with the neurosurgeons, like it's being it's being placed in a very, very sort of uh high quality way as well.
00:38:37.280 --> 00:38:46.239
So so I I you know when I read it, I I it's nice to hear that the post op SRS was high quality, and then I I would expect that the the break therapy was as well.
00:38:46.320 --> 00:38:47.679
So that's that's nice yeah.
00:38:48.079 --> 00:38:53.199
The other data point that we have regarding like the quality of the SRT was the necrosis finding.
00:38:53.280 --> 00:38:56.639
It was 5.7%, which is you know lower than historic.
00:38:56.719 --> 00:39:00.159
I think typically like there was a meta-analysis published a few years ago.
00:39:00.320 --> 00:39:07.280
Um necrosis rates would you can can be sometimes double digits uh for post-op SRT, particularly single fraction.
00:39:07.440 --> 00:39:13.679
And so that 5.70 rate is, I think, um also speaks to like the thoughtfulness and the quality of the post-op SRT.
00:39:13.760 --> 00:39:20.159
The the radiation necrosis rate, just for uh context on the gamutile arm was 5.2%, and there was no difference between the two.
00:39:20.559 --> 00:39:21.280
That's a
good point.
00:39:21.519 --> 00:39:30.320
Well, I want to ask you one thing before we, and I'm gonna come back to that actually as one of our last topics to talk about this study, but I wanted to ask you before we move on about pre-op SRS.
00:39:30.480 --> 00:39:34.159
So I saw somebody float the idea that that would have been a better control arm.
00:39:34.320 --> 00:39:46.960
That to me is like the most armchary uh investigator point, because I think this when, especially when I'm guessing this was designed and written, absolutely pre-op SRS was not considered a standard of care.
00:39:47.119 --> 00:39:51.599
But I saw this comment and I actually went and looked this up because I was like, should I be doing more of this?
00:39:51.679 --> 00:39:52.880
Is it considered standard?
00:39:53.119 --> 00:39:54.320
I I would argue it's not.
00:39:54.480 --> 00:39:58.559
I actually think if you look at different guidelines, it does give you permission to do it.
00:39:58.719 --> 00:40:02.960
But I would say it's pretty aggressive statement to say that it's standard.
00:40:03.039 --> 00:40:07.679
Uh if you consider like what, you know, like looking at guidelines and the way that people are doing things.
00:40:07.840 --> 00:40:17.599
But one thing that I do think worth is that's worth pointing out that is a fair critique is that if you compare pre-op SRS to post-op SRS, the control outcomes are just better.
00:40:17.760 --> 00:40:19.760
And so, so any thoughts on that at all?
00:40:20.079 --> 00:40:21.440
This is a super off topic.
00:40:21.679 --> 00:40:22.000
Yeah.
00:40:22.079 --> 00:40:34.079
Um pre-op, uh, I agree with your statement in that the level of evidence that supported post-op SRT to become this area of care was, you know, it relied on phase three data.
00:40:34.559 --> 00:40:39.280
Um now with with now gamma tile has phase three data behind it.
00:40:39.519 --> 00:40:43.039
BN012 does not yet have phase three data behind it.
00:40:43.199 --> 00:40:54.960
We are um awaiting the results of BN012, which is a post-op SRT versus pre-op SRT trial, that I believe is done accruing, and I'm really looking forward to that trial reading out.
00:40:55.199 --> 00:41:04.400
If BN012 is positive for pre-operative SRT, then I think it would be reasonable to say that it could be a standard of care.
00:41:04.960 --> 00:41:19.920
Um, and then I I think that if so, if pre-op SRT is better than post-op SRT on that randomized trial, and we know gamma tile is better than post op SRT on the Rhodes trial, then you may have clinical equipoise between pre-op SRT and gamma tile.
00:41:20.480 --> 00:41:23.760
Both at that point should be considered standard options.
00:41:24.239 --> 00:41:31.599
And um, and then at that point, you could justify a trial between those two because both would then have been superior to post-op SRT.
00:41:31.920 --> 00:41:40.559
But I would love to speak a little bit to the um the local control rates that we are seeing with early not randomized data.
00:41:40.880 --> 00:41:51.199
Um, two have been presented in 2026, to my knowledge, maybe more, but there was um a Japanese trial presented at ASCO called the neotactic study.
00:41:51.280 --> 00:41:53.679
There was a single arm fractionated pre-op.
00:41:53.920 --> 00:41:56.960
Because there's a local question of fractionated pre-op or single-fractured pre-ops.
00:41:57.039 --> 00:41:57.599
That's right.
00:41:57.760 --> 00:42:07.840
But the the field is there's retrospective data that suggests that, and then now prospective single arm data that suggests that fractionated pre-op is better than single fractured pre-op.
00:42:08.320 --> 00:42:20.559
So um the the neotactic study presented from um uh Japan at ASGO showed a 12-month local control rate of uh 83.6 percent.
00:42:21.199 --> 00:42:29.599
And then the STEP trial was just published in um neuro oncology from France that showed a 12-month local control rate of 96.4%.
00:42:30.079 --> 00:42:39.760
So I think it's at this point with single arm studies, we're looking at um mid-80s to mid-90s percent.
00:42:40.480 --> 00:42:47.440
The local control rate on um the on the on the roads trial for gamma tile was a pro was was approximately 98%.
00:42:48.320 --> 00:43:04.079
So I think that we that that it may be that pre-op SRTs rather than post-op SRT, those local control rates could could you know be read as quite similar, and then and then you could, you know, then I could see like the justification for a trial between those two.
00:43:04.880 --> 00:43:06.719
Yeah, I think that's a great, great description.
00:43:06.880 --> 00:43:08.960
Thank you for uh reviewing those other studies as well.
00:43:09.119 --> 00:43:10.320
I think it's an evolving space.
00:43:10.480 --> 00:43:13.119
Something I'm thinking about more, but but I thought it was an interesting comment.
00:43:13.519 --> 00:43:28.320
The other consideration for pre-op, just uh a couple more thoughts on it, is um these patients with brain mets, they're with surgical brain mets, they're often, I'm I mean, in my clinical experience, over 90% of the time presenting to the emergency department with neurologic symptoms.
00:43:28.639 --> 00:43:32.719
Um and they have to be to craniotomy quite urgently.
00:43:32.960 --> 00:43:43.199
So pre-op, I think conceptually can make a lot of uh sense in terms of you know radiating an easier target, sterilizing MO4 resection, um, preventing L and D.
00:43:43.519 --> 00:43:48.960
But logistically and practically, I do think that there are some things that require consideration.
00:43:49.280 --> 00:44:03.199
When a patient needs to be taken to the ER relative or sorry, to the OR relatively urgently, you know, to do the CT simulation planning and then to give the radio surgery, you Are inherently delaying the surgery.
00:44:03.679 --> 00:44:11.119
And also sometimes, you know, it is difficult to deliver radio surgery in the hospital for reimbursement purposes.
00:44:11.280 --> 00:44:16.880
And I know sometimes hospitals, you know, that that can be challenging to do that in the hospital.
00:44:16.960 --> 00:44:26.320
And then to discharge a patient who has been admitted with neurologic symptoms from mass effect on the brain, you know, to do radial surgery, one could question the appropriateness of that.
00:44:27.280 --> 00:44:28.559
Okay, I'm gonna pivot.
00:44:28.800 --> 00:44:29.119
Okay.
00:44:29.360 --> 00:44:33.360
Um just because I want to keep us on we we probably could do this for like two hours.
00:44:33.440 --> 00:44:35.519
So I'm gonna keep us on track here.
00:44:35.760 --> 00:44:50.880
Um so so I wanted to go back a little bit, and this is uh separate from bridges, because or sorry, from Rhodes, sorry, because I because I don't I don't uh think this was something that was like discussed thoroughly, and I'm not asking you to comment on it specifically from Rhodes, but more of a higher level kind of global comment.
00:44:51.119 --> 00:45:07.199
Two things that have been interesting to me about a sort of theoretical edge of gamma tile over SRT, whether it's pre or post op, uh, is gonna be uh a reduction in risk of radiation necrosis, and then also a reduction in risk of leptominingal disease.
00:45:07.280 --> 00:45:11.440
And I want to emphasize for the listeners that this is like consider this an exploratory discussion.
00:45:11.519 --> 00:45:23.199
We're not making any definitive statements about this, but these are two aspects I've talked about with my own group that um, and when we're thinking about comparing it to the alternative options like SRS, what are your thoughts on those two endpoints for patients?
00:45:23.360 --> 00:45:24.480
To me, they matter a lot.
00:45:24.639 --> 00:45:25.360
So yeah.
00:45:25.760 --> 00:45:27.360
They they really matter a lot.
00:45:27.599 --> 00:45:37.920
Um, on the root study, did it appear that there's any differences between radiation necrosis um uh on on the gamutile arm versus on the uh post-op SRT arm?
00:45:38.239 --> 00:45:51.280
Uh at leptom meningial disease was evaluated, and um statistically there was no difference between L and D on the on the um post-op MRT, post-op SRT arm and on the gamutile arm.
00:45:51.760 --> 00:46:03.199
Numerically, there on on the cumulative incidence, numerically there was more L and D on the gamutile arm on the uh analysis of probability of leftamaningal disease-free survival.
00:46:03.360 --> 00:46:08.880
Numerically, uh there were more advanced upon the SRT arm, but neither were statistically significant.
00:46:09.119 --> 00:46:15.199
I think, and in part takeaway is that there was no difference in L and D between gametile and post-op SRT.
00:46:15.519 --> 00:46:25.760
Um, but for pre-operative radiation, which you know conceptually sterilizes the tumor before resection, should um prevent L and D.
00:46:25.840 --> 00:46:30.159
And we are seeing very low rates of LMD with pre-operative radial surgery.
00:46:30.320 --> 00:46:36.800
Um in the two trials that I mentioned, I believe that there was a 0% risk of or a 0% rate of LND.
00:46:37.039 --> 00:46:40.480
So L and D is really, really clinically meaningful, as you said.
00:46:40.639 --> 00:46:48.400
And the type of LND that I know pre-op is trying to prevent is nodular L and D or pachy meningial LMD or seeding of the surgical tract.
00:46:48.719 --> 00:46:58.880
And so people are really interested in this composite endpoint, and that's the primary endpoint of BN012 of uh a surgical bed recurrence or leptomeningal disease or radiation necrosis.
00:46:59.360 --> 00:47:12.800
And and I do think that if BN012 reads out as positive for pre-op, then then that composite endpoint, I think that there could be clinical echo points again between gametel and pre-op SRT.
00:47:13.360 --> 00:47:22.000
Um so these are all very meaningful, you know, components of the post-operative care for a patient who receives radiation for resective brain mass, as you said.
00:47:22.480 --> 00:47:25.760
It's always been a little bit of a mystery, maybe the whole like seeding after surgery.
00:47:25.840 --> 00:47:29.599
I think we've had a lot of across disease sites and studies, we've tried to address this.
00:47:29.760 --> 00:47:32.079
It's been challenging and not consistent.
00:47:32.320 --> 00:47:39.920
So one thing that's been of interest um is how do you reduce LMD with gamut like with a gamutile implant?
00:47:40.079 --> 00:47:49.199
And you know, it took so but even the the thinking, it's still controversial with post op SRT as to like how far do you chase the cavity, especially for like a deep-seated tumor?
00:47:49.360 --> 00:47:49.599
Yeah.
00:47:49.760 --> 00:47:53.679
Um, so I think that you know the same thinking is applying for gametile.
00:47:53.840 --> 00:47:57.119
Like if it's a deep-seated tumor, should you tile the tract?
00:47:57.599 --> 00:48:05.440
Or for a dirt, you know, a tumor that's involving the dura, should you provide some extra tile there to provide some dural margin?
00:48:06.000 --> 00:48:25.199
So I think one opportunity um that I know the some investigators are interested in is looking at the cases of nodular L and D on the Gannel tile arm to see like if the tile had been placed, if there had been you know more tiling of the tract, for instance, or or along the dura, could that have prevented that nodular recurrence?
00:48:25.360 --> 00:48:30.800
So I think that's a really interesting question and an opportunity to better understand how to how to tile.
00:48:31.360 --> 00:48:44.320
Yeah, one of the things that one of the things that I always have in the back of my head is, I mean, obviously I think as a radiation oncologist, it's like in our DNA to think about like, is the recurrence uh can it be explained by like underdosing?
00:48:44.559 --> 00:48:44.800
Right.
00:48:45.199 --> 00:49:00.159
But I think what we if you go like way back and you just look across disease sites with tracking tumor and coverage of you know,
surgical beds and things like that, surgical incisions, it's it's I I worry that biology is undermining our ability to understand this problem.
00:49:00.400 --> 00:49:06.800
Because I I I have to wonder if there's just some cancers that have a propensity of that and we just don't have a way to detect it.
00:49:06.960 --> 00:49:19.199
And so, like if you just randomize everyone, um, as like you know, I'm I'm thinking of like the uh uh like the port study, the one that where they did uh uh like mesothelioma kind of incision sites, see the prophylactic radiation there.
00:49:19.360 --> 00:49:24.559
And it's like maybe for some patients, it's not a concern because biologically the tumors just won't do that.
00:49:24.719 --> 00:49:29.440
Um, I I cut my teeth as an independent doctor doing sarcoma as a specialty.
00:49:29.760 --> 00:49:39.360
And you know, we're in a place, I think, in sarcoma, where we're not chasing drain sites and things like that anymore, uh, mainly because just like in brain, it's a very functional area.
00:49:39.440 --> 00:49:45.199
So the more you radiate, the kind of more side effect and physical function limitation you have with patients.
00:49:45.280 --> 00:49:56.400
And so it's just, I think you're uh I just wonder if if like until we have a way to detect these people up front, it's gonna be challenging to prove that prophylactically treating it is is better.
00:49:56.559 --> 00:50:01.679
Um, this is purely just my own like crazy thoughts about the space, just looking across cancers.
00:50:01.840 --> 00:50:03.360
Uh, I don't know if that is anything, you know.
00:50:03.440 --> 00:50:06.800
I mean, I'm not a brain specialist, so I think in general it's something that I just think about.
00:50:07.199 --> 00:50:09.360
Yeah, no, I I I think you're absolutely right.
00:50:09.519 --> 00:50:19.199
And I think we need to do a better job predicting, um, as you said, for really for any disease site, how to better, you know, prevent a bad outcome, including like leptom and angel disease.
00:50:19.360 --> 00:50:20.079
Um, all right.
00:50:20.239 --> 00:50:21.199
So let me do this.
00:50:21.280 --> 00:50:32.000
I'd like to do one topic here, and then I think it'll be a nice lead-in to the next discussion that we have, this issue of like regulation, adoption, costs, that kind of a thing.
00:50:32.159 --> 00:50:43.360
Um, and and so my one thing that I like that has already come up for me a few times is that um gametile is FDA approved for all brain tumors, right?
00:50:43.599 --> 00:50:51.360
And so uh I don't you can correct me on that, but basically, this is something that patients have found to me, and then they come to me and say, well, why is there a trial?
00:50:51.519 --> 00:51:12.719
And so I'm curious if you could share a little bit of your thoughts about uh uh first uh that fact, and then um how it might affect like sort of implementation equipoise among radiation oncologists that are thinking about launching a program, and then
how people might deal with that if they're enrolling to the studies that gamutile is running because patients do ask about it.
00:51:12.960 --> 00:51:13.199
Sure.
00:51:13.599 --> 00:51:13.760
Yeah.
00:51:14.079 --> 00:51:15.119
Thank you for asking that.
00:51:15.280 --> 00:51:21.599
Um this is like a really important thing that that that comes up a lot, especially as as patients ask about gamutile.
00:51:22.000 --> 00:51:28.480
So gamma tile is FDA cleared for any malignant brain tumor and any recurrent brain tumor.
00:51:28.639 --> 00:51:38.000
So malignant brain tumors bring you know brain mats, GBM, recurrent brain tumors would would include those things as well, but also it could include uh recurrent um meningoma.
00:51:38.400 --> 00:51:42.480
So it does have a uh a relatively broad FDA clearance.
00:51:42.719 --> 00:51:48.239
Um and so why you know, why do trials?
00:51:48.559 --> 00:51:53.519
Well, in oncology, you know, we're in that we're we're obviously and thankfully an evidence-based field.
00:51:53.760 --> 00:51:59.679
And thankfully, for many of the disease settings, we can lean on randomized data.
00:52:00.000 --> 00:52:06.400
And and then there are some disease settings, unfortunately, where there may not be randomized data that exists, but we still want data.
00:52:06.639 --> 00:52:13.519
Fortunately, for brain mats, there is quite a bit of randomized data that has led to the evolution of the standard of care.
00:52:13.840 --> 00:52:17.920
And so now with resective brain mats, we can lean on this randomized data.
00:52:18.079 --> 00:52:28.400
So when a patient wants to know their treatment options, you know, we can educate them on the data that supports the use of gametile for their uh recycled brain metastasis.
00:52:28.719 --> 00:52:36.800
Um for you know things like recurrent glioblastoma that is that is on our label under a malignant brain tamer.
00:52:37.360 --> 00:52:51.039
Unfortunately, we don't have any randomized data that supports really any approach for recurrent GBM that shows an overall survival benefit with some you know with some caveats, um, but certainly in the brain space, a brain radiation space, we don't.
00:52:51.199 --> 00:53:01.440
And so then we rely on some prospective single arm studies or retrospective studies to you know be able to assess which patients could benefit from this modality.
00:53:01.840 --> 00:53:12.000
So I think that although we have the clearance, we should still heavily rely on you know published data to inform us on you know which patients could be appropriate for gametiles.
00:53:12.320 --> 00:53:24.239
I think that the that the actual clinical data um is is at least as a clinician, is is um more important and should be in addition to you know FDA clearance or an FDA approval.
00:53:24.639 --> 00:53:24.800
Yeah.
00:53:24.960 --> 00:53:32.320
And I think what I've done actually in this when pay this has come up actually twice already in like in the last couple months for me, just where a patient directly asks me.
00:53:32.400 --> 00:53:37.760
And and it actually is a nice opportunity to talk to patients about how regulation in medicine actually works.
00:53:38.239 --> 00:53:39.519
I think most people don't get it, right?
00:53:39.599 --> 00:53:49.360
And I think that they really do appreciate at least my discussion of it, because the reality is is like I tell people like you you can do this, but is it the right thing to do?
00:53:49.440 --> 00:53:50.079
Is really the question.
00:53:50.320 --> 00:53:55.280
Yeah, that is, I think that is everything I said in a much in a nutshell in a much more eloquent way.
00:53:55.360 --> 00:53:57.119
Like, just because you can't doesn't mean you should.
00:53:57.840 --> 00:54:01.360
And then I don't have a regulatory background, so I hope I get this right.
00:54:01.519 --> 00:54:07.920
So I we we have a clearance, which you know, typically you could have a like a predicate, you show some safety.
00:54:08.000 --> 00:54:09.440
Um, first is an approval.
00:54:09.519 --> 00:54:11.519
Uh Gamma Trial does not yet have approval.
00:54:11.679 --> 00:54:15.840
I do think that the Rhodes trial paves uh a pathway to getting approval.
00:54:16.079 --> 00:54:20.000
Typically, an approval requires a very high level of evidence.
00:54:20.559 --> 00:54:35.280
And so um, I think for a clearance, like you know, having this clinical data really supports the the the gradient colleges to offer this on top of you know the clearance.
00:54:35.679 --> 00:54:40.719
Um and and and the hope is to have an approval to use this very high level of evidence to then get an approval.
00:54:40.800 --> 00:54:43.679
But usually to have an approval, you have to have that very high level of evidence.
00:54:43.840 --> 00:54:47.760
So, you know, uh yeah, hopefully we can't.
00:54:47.840 --> 00:54:54.960
I'm I'm sort of laughing a little because I've been visioning a lawyer like screaming at his at his car stereo at me because I I totally I think I said approval in the question.
00:54:55.039 --> 00:54:56.480
It's a good clearance.
00:54:56.719 --> 00:55:01.199
I'm also not a regulatory person, so I think people should be to take to take this discussion with a grain of salt.
00:55:01.280 --> 00:55:11.440
But I think that's yeah, the important part I think though is like is is that um it's it's interesting because I think you you you do as a physician need to think about this.
00:55:11.599 --> 00:55:17.599
I'm gonna put it in the sh in the show notes because I love this this study, but there was a study by I think uh uh Dr.
00:55:17.760 --> 00:55:24.159
Jagsy that looked at what what they call therapeutic misconception with new devices in radiation oncology.
00:55:24.239 --> 00:55:29.519
And it and it's an important thing to think about because like uh we'll talk about this is a nice segue to the bridges trial.
00:55:29.599 --> 00:55:30.079
We'll talk about that.
00:55:30.159 --> 00:55:31.039
We have that open here.
00:55:31.119
--> 00:55:37.119
And when I talk to patients about it constantly in the discussions, they talk about drawing the short straw, like all this thing.
00:55:37.199 --> 00:55:38.079
I'm like, no, no, no.
00:55:38.159 --> 00:55:46.000
Like you need to understand, like, especially in glioblastoma, like this is a disease where we've tried so many things and it turns out to be like the same very often.
00:55:46.159 --> 00:56:02.000
And so, so I I try really, really hard, but it's so like I think of that paper almost on a weekly basis now because I think patients are just the culture we live in, it's an exciting technology, but I think medicine is just so much more complicated than people appreciate.
00:56:02.159 --> 00:56:03.679
Even some doctors appreciate, I think.
00:56:03.760 --> 00:56:10.320
And and we've had so many predictions where we were so sure things were going to be right and great, and then it just turns out to be the same or sometimes even worse.
00:56:10.400 --> 00:56:13.039
And so that's why trials are important and I do share that.
00:56:13.119 --> 00:56:25.840
And I think ultimately what's come of my discussions is people really appreciate that, and then they feel very proud that they're contributing to a literature that's helping patients 10, 20 years from now, have the best available therapy based on what we learn from these studies.
00:56:26.000 --> 00:56:26.960
So totally agree.
00:56:27.039 --> 00:56:31.840
And and thanks so much for enrolling on um the Bridges study and you know, happy to talk about that too, if that's helpful.
00:56:32.079 --> 00:56:34.000
Yeah, let me slip one thing in before we get to that.
00:56:34.079 --> 00:56:34.800
We'll close with that.
00:56:34.960 --> 00:56:51.519
I wanted to just share that um, I wanted to actually kind of share that we launched this program relatively recently uh in our network, and it's something that's generated a lot of excitement um to the point where we're having this discussion now, like kind of back and forth about like what is, you know, where are we using this?
00:56:51.679 --> 00:56:56.079
Where do we implement this, for which patients is ideal, those kinds of things, like boots on the ground.
00:56:56.320 --> 00:57:05.440
But I do want to point out to the audience that one of the things I really appreciated is at Denver healthcare is just really, really hard.
00:57:05.760 --> 00:57:08.480
Implementing this has been shockingly easy.
00:57:08.559 --> 00:57:11.360
And and it does take multidisciplinary coordination.
00:57:11.440 --> 00:57:37.920
But one thing that I really have appreciated is the plethora of materials available to physicians to educate themselves about this, get ready for that first consult, talk with the neurosurgeons, and then uh the resources available to our physics team to basically get the entire staff and multi-d group ready for the regulatory uh aspects of implementing a program like this, you know, with because it's a radioactive material.
00:57:38.079 --> 00:57:47.199
And so, you know, I I'll I'll put the link in the show notes, but I did want to point people to these materials because genuinely it was like we did so much work to get this going.
00:57:47.360 --> 00:57:50.559
The the the couple days before my first consult, I'm prepping for it.
00:57:50.639 --> 00:57:52.800
And I just wrote our our rep on the ground here.
00:57:52.880 --> 00:57:55.119
I just said, hey, like what kind of materials do you guys have?
00:57:55.199 --> 00:57:57.039
And he's like, Oh, let me let me send this to you.
00:57:57.119 --> 00:58:05.199
And and and it was just so much and and it was so well organized that I felt like I could I got like a boot camp and like an hour of rooting to basically go through everything.
00:58:05.280 --> 00:58:29.840
And so so I did want to point those materials out to people and and I would I would encourage listeners, if they're excited by this conversation, not to let the fear of launching a program be the barrier because it is it it's I'm not gonna say it's easy, but it was actually a lot uh more well supported than I would have expected uh by work, you know, based on working with other industry partners and things like that.
00:58:30.159 --> 00:58:31.199
Thank you for saying that, Matt.
00:58:31.360 --> 00:58:41.599
I know the company works really hard to support docs as as best as we can to make it as easy as possible to um you know provide this as an option to patients.
00:58:41.760 --> 00:58:46.320
We we know that docs need all the options that they can have taking care of these patients.
00:58:46.480 --> 00:58:51.280
And so um I know the company aims to try to make it as easy as possible on on the docs.
00:58:51.920 --> 00:59:04.079
Yeah, and it's and it's important to like like we said at the top, it's important always to be skeptical when implementing new things based on you know new scientific studies, but when you're ready to do it, having those materials and resources is just very supportive.
00:59:04.159 --> 00:59:04.880
So that's nice.
00:59:05.039 --> 00:59:06.880
Let's let's go to one of our last topics here.
00:59:06.960 --> 00:59:08.639
I want to talk about the bridges trial.
00:59:08.719 --> 00:59:11.440
So so this is this is really exciting.
00:59:11.599 --> 00:59:18.880
Um, and so can you summarize the kind of top line design of the bridges trial and what it's aiming to achieve?
00:59:19.039 --> 00:59:21.199
This is open now and enrolling.
00:59:21.360 --> 00:59:21.519
Yeah.
00:59:21.760 --> 00:59:22.000
Yes.
00:59:22.239 --> 00:59:27.039
The bridges study is for newly for patients with newly diagnosed glioblastoma.
00:59:27.360 --> 00:59:33.440
And it is building off of the the the trial, the feasibility study called Gestalt.
00:59:33.840 --> 00:59:55.360
So gestalt enrolled patients with uh suspected newly diagnosed glioblastoma based on imaging, um, implanted if frozen section confirmed high-grade glioma, implanted gametile at the resection to
start radiation immediately and then bridge the patient over to external beam radiation with concurrent hemazolamide.
00:59:55.840 --> 01:00:10.559
With the hypothesis being that starting radiation immediately would close the treatment gap for this very malignant, highly proliferative tumor that can start growing back right after surgery and thereby hopefully improve outcomes.
01:00:10.800 --> 01:00:17.440
Uh the Gestalt study showed that it was dosymetrically feasible to add on um a spatial margin using IMRT.
01:00:17.519 --> 01:00:26.639
And what I mean by spatial margin, I mean that um this methodology isn't only meant to dose-escalate, but rather time intensify the treatment.
01:00:26.800 --> 01:00:34.400
So gametiles uh get gives the dose the cavity into the first approximate five millimeters or so where recurrences are most likely to happen.
01:00:34.639 --> 01:00:35.840
It can happen early.
01:00:36.000 --> 01:00:43.920
And then the IMRT is added on kind of like a donut to provide that additional spatial margin that is standard of care for this infiltrative tumor.
01:00:44.320 --> 01:00:50.639
Um the patients then have the standard adjuvant chemozolamide a month after completion of chemoradiation.
01:00:50.960 --> 01:00:58.079
And um, so this really kind of um builds off the standard of care by starting radiation immediately.
01:00:58.480 --> 01:01:18.719
The outcomes from uh Gastal were presented at ASCIIO this this past May, which showed um a very favorable safety profile in line with what you'd expect with the standard of care, and showed a very low rate of what's termed rapid early progression, that early tumor regrowth between surgery and radiation planning MRI, which is uh associated with worst outcomes.
01:01:19.039 --> 01:01:25.840
In the literature, and Mayo has done a lot of work here, have has shown um a rapid early progression rate of inward between 40 to 60 percent.
01:01:25.920 --> 01:01:27.519
It was six percent on this cult.
01:01:27.920 --> 01:01:36.480
Um, so these things have motivated the opening of bridges, which is a phase three trial comparing that methodology to the standard of care.
01:01:36.719 --> 01:01:42.400
And as you mentioned, we that we this trial activated at the end of December and it is enrolling very, very well.
01:01:42.639 --> 01:01:48.079
We've been super, super excited to partner with you, Matt, and your center as well as um other centers across the country.
01:01:48.159 --> 01:01:51.760
There's now over 20 enrolling centers, and there's been over 60 enrollments to date.
01:01:51.920 --> 01:01:54.079
So it's it's enrolling way ahead of projection.
01:01:54.239 --> 01:01:55.920
So yeah.
01:01:56.079 --> 01:01:57.199
Yeah, congratulations for that.
01:01:57.280 --> 01:01:57.760
It's fantastic.
01:01:57.840 --> 01:01:58.800
It's a large trial, right?
01:01:58.880 --> 01:02:03.840
I think you get did you sorry if you said this already, but it's good uh looking to enroll like 700 people or that's right.
01:02:03.920 --> 01:02:04.960
Yeah, no, I hadn't said that.
01:02:05.039 --> 01:02:14.400
It's uh the it the it can enroll up to uh uh 700 over 700 patients, and there are gonna be a couple income analyses that could lead to early stoppage.
01:02:14.559 --> 01:02:16.159
So yeah, exactly.
01:02:16.400 --> 01:02:24.559
Yeah, and if people if people know me, like I've been a little vocally frustrated that we keep trying to dose intensify over and over again.
01:02:24.639 --> 01:02:28.000
Uh, and it just hasn't hasn't been a great strategy, I think, in general.
01:02:28.079 --> 01:02:30.719
And so I think time intensification is really clever.
01:02:30.880 --> 01:02:38.480
And and honestly, when I talk to patients about this, I I just say, look, like if I was in your shoes, I I like new ideas in this space.
01:02:38.559 --> 01:02:40.400
This is a challenging tumor to treat.
01:02:40.480 --> 01:02:42.800
Um, we've gotten excited about new ideas in the past.
01:02:42.960 --> 01:02:47.360
There's been viral vectors and different options for trying to intensify therapy that way.
01:02:47.519 --> 01:02:56.719
Um, and and so I'm just personally just at a very high level, I'm excited to hear like a new approach to trying to improve outcomes for this kind of a patient population.
01:02:56.880 --> 01:02:58.159
I think it's just a nice thing to see.
01:02:58.559 --> 01:02:58.880
Thank you.
01:02:59.119 --> 01:02:59.360
Yeah.
01:02:59.440 --> 01:03:02.880
Can I one thing I wanted to close with, let me come back to this therapeutic misconception thing.
01:03:02.960 --> 01:03:12.320
So on your Rhodes trial, so the the Metz trial, I think I saw that uh by randomizing before surgery, there was about 11% of patients that dropped out of the of the analysis.
01:03:12.480 --> 01:03:13.119
Are these separate?
01:03:13.199 --> 01:03:16.159
These are separate from the ones where the histology was a surprise, right?
01:03:16.320 --> 01:03:21.199
So this is like someone who gets enrolled and then drops out because they don't like the arm.
01:03:21.760 --> 01:03:26.159
Um maybe I'm off on that statistic, but the concept is important, right?
01:03:26.239 --> 01:03:28.400
And so the same thing in bridges, right?
01:03:28.480 --> 01:03:30.400
We're enrolling prior to surgery.
01:03:30.559 --> 01:03:39.679
And I already kind of shared that I've had this conversation multiple times already with patients where there's just this uh, there's just a desire to like get to the experimental arm.
01:03:39.840 --> 01:03:43.280
There is a two-to-one randomization, so that helps with that design.
01:03:43.519 --> 01:03:48.880
But do you have advice just for people who are enrolling site PIs, trialists in general?
01:03:49.119 --> 01:03:55.280
I think it's a cool uh thing to talk about, and it's something that will consistently be a problem in our field because we're so technology driven.
01:03:55.440 --> 01:04:01.039
So, thoughts on how to present this to patients or issues that you've had
or anything like that you could discuss there?
01:04:02.079 --> 01:04:02.880
Uh totally.
01:04:03.039 --> 01:04:04.559
And you're right about that statistic.
01:04:04.639 --> 01:04:14.320
There were some dropouts between um randomization and surgery, um, presumably because some patients, you know, were hoping to get randomized to the gametile arm.
01:04:14.639 --> 01:04:26.960
Um and this is a this is a problem with any non-blinded study, which of course, you know, in radiation oncology, it's incredibly difficult to do a non-blinded study, particularly when you're comparing across two very different radiation modalities.
01:04:27.280 --> 01:04:31.920
And so um, in terms of how to talk to patients, I I love what you're doing.
01:04:32.000 --> 01:04:40.320
Um and I I think what you're doing is really a model for how people should enroll, which is telling patients, you know, we don't know what the right thing to do is.
01:04:40.559 --> 01:04:46.079
But you being part of this trial benefits you and benefits others um in the future.
01:04:46.239 --> 01:04:52.880
It can benefit you because patients who are on trial are gonna have a lot more attention, a lot more resources.
01:04:53.119 --> 01:05:00.559
Um and and in that way, like no matter which arm you get randomized to, you're gonna benefit from being on this trial.
01:05:00.960 --> 01:05:07.760
And because we don't know which one is better, it is totally fine to be randomized to the non-experimental arm.
01:05:08.000 --> 01:05:12.159
And as you mentioned before, sometimes people do better on the non-experimental arm than the experimental arm.
01:05:12.800 --> 01:05:15.679
So the way that you go about that is perfect.
01:05:15.920 --> 01:05:18.719
And I think that's really like how people should go about that.
01:05:19.199 --> 01:05:26.960
I think that if people, you know, perhaps you may talk up too much an experimental arm, then the patients could be disappointed.
01:05:27.199 --> 01:05:27.360
Yeah.
01:05:27.599 --> 01:05:32.320
So I I think it's really a matter of, you know, educating the patient like exactly as as you are not.
01:05:32.480 --> 01:05:34.239
I think that, yeah, that's exactly what I would do.
01:05:34.480 --> 01:05:40.159
Yeah, and I do think I do think radiation oncologists are uniquely positioned to do that well for patients, like in this setting.
01:05:40.320 --> 01:05:48.239
Um, uh just uh, you know, I think in general it's something that that overall people should take on, and it's a really nice service for patients overall.
01:05:48.559 --> 01:05:48.880
All right.
01:05:48.960 --> 01:05:51.920
Well, so that that was what I had for today.
01:05:52.079 --> 01:05:53.840
Um, I think this has been fantastic.
01:05:53.920 --> 01:05:55.199
I always love having you on.
01:05:55.440 --> 01:06:04.239
Do you have any final uh I'm gonna give a final thought, but do you have any final thoughts before we kind of close out about roads, gametile, the future, things like that?
01:06:04.559 --> 01:06:19.280
Uh I really just kind of want to express my gratitude to to you and to all the investigators across these studies to, you know, for for working hard to enroll patients and really across all clinical trials, because all these patients, like they they definitely need better options, right?
01:06:19.440 --> 01:06:28.320
And gamutile is another um tool in our arsenal to care, take care of these patients, in addition to all the other types of radiation, all the systemic therapies.
01:06:28.480 --> 01:06:31.360
And we need all the help that we can get to take care of these patients.
01:06:31.440 --> 01:06:44.400
And so I just super appreciate the work that you're doing and the work that all our colleagues are doing across the country um in enrolling on these gamutile studies, but also just you know enrolling in generally um for for patients.
01:06:44.480 --> 01:06:46.719
So that's kind of like I think that's kind of like my final thought.
01:06:46.880 --> 01:06:51.760
It's it's been it's been one of the privileges in my life to be able to like participate in something like this.
01:06:52.079 --> 01:06:52.960
No, I think that's awesome.
01:06:53.039 --> 01:06:59.360
And I would say that one thing you said that sticks with me always is just this this concept of the armamentarium, right?
01:06:59.440 --> 01:07:04.480
I think people who are busy clinicians, like you're there, you're wanting to help people.
01:07:04.639 --> 01:07:12.400
And I think we all know that like with a lot of patient populations, our one of our biggest limitations is the tools we have available to us to treat them, right?
01:07:12.480 --> 01:07:27.920
And so one of the things I've been so appreciative of is the people who not just get not just gametile, but the people who are developing new technologies that give us new options for patients because it adds robustness to our tumor board discussions, it adds options for people to talk about.
01:07:28.079 --> 01:07:31.760
And then, of course, clinical trials are always a really nice thing to offer to patients.
01:07:31.920 --> 01:07:40.480
So so uh I would encourage the audience really to uh generally be can be critical, be suspicious, be thoughtful about the things that you're implementing.
01:07:40.639 --> 01:07:55.840
But I think that the data presented here uh at least gives a very strong argument that you uh should strongly consider adding this to the our inventarium and then working it in in different uh indications in your kind of brain tumor uh conferences and things like that.
01:07:56.079 --> 01:07:56.320
All right.
01:07:56.400 --> 01:07:57.199
Well, thank you very much.
01:07:57.280 --> 01:07:58.400
I really appreciate your time.
01:07:58.480 --> 01:08:04.480
Uh hopefully we'll have you back in maybe a couple years when Bridges results out and we can talk about it again.
01:08:04.559 --> 01:08:09.920
And so just uh just um uh I look forward to kind of talking to you in the future and and more to come on all of this.
01:08:10.079 --> 01:08:10.800
Yeah, thanks, Matt.
01:08:10.960 --> 01:08:11.360
Love coming on.
01:08:11.599 --> 01:08:15.039
We take the opportunity to get to us today.
01:08:20.159 --> 01:08:21.279
Thanks for listening.
01:08:21.600 --> 01:08:24.800
If you liked our show, please subscribe and leave us a rate.
01:08:25.279 --> 01:08:28.479
We hope you're having a great day and look forward to seeing you again soon.